Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Patent
1993-03-31
2000-04-18
Cunningham, Thomas M.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
4241551, 5303873, 5303888, 53038885, 5303913, 5303917, 435 792, A61K 39375, C07K 1630
Patent
active
060512253
ABSTRACT:
This invention concerns a family of chimeric antibodies with high affinities to a high molecular weight, tumor-associated sialylated glycoprotein antigen (TAG-72) of human origin. These antibodies have (1) high affinity animal V.sub.H and V.sub.L sequences which mediate TAG-72 binding and (2) human C.sub.H and C.sub.L regions. They are thought to produce significantly fewer side-effects when administered to human patients by virtue of their human C.sub.H and C.sub.L antibody domains. The nucleotide and amino acid sequences of V.sub.H .alpha.TAG V.sub.H, CC46 V.sub.H, CC49.sub.H, CC83 V.sub.H, and CC92 V.sub.H, and CC49.sub.L, CC83 V.sub.L, and CC92 V.sub.L idiotype sequences are disclosed, as well as in vivo methods of treatment and diagnostic assay using these chimeric antibodies.
REFERENCES:
patent: 4522918 (1985-06-01), Schlom et al.
patent: 4612282 (1986-09-01), Schlom et al.
patent: 4642334 (1987-02-01), Moone et al.
patent: 4656134 (1987-04-01), Ringold
patent: 4800159 (1989-01-01), Mullis et al.
patent: 4867973 (1989-09-01), Goers et al.
patent: 4978745 (1990-12-01), Schoemaker
patent: 5091513 (1992-02-01), Huston et al.
Whittle, et al. (1987), Protein Engineering, 1(6):499-505.
Rice, et al., (1982), Proc. Natl. Acad. Sci., USA, 79:7862-7865.
Oi, et al. (1983), Proc. Natl. Acad. Sci., USA 80:825-829.
Boulianne et al. (1984), Nature, 312:643-64.
Cabilly et al. (1984), Proc. Natl. Aca. Sci., USA, 81:2955-2959.
Kenten et al. (1984), Proc. Natl. Aca. Sci., USA, 81:2955-2959.
Lui et al. (1984), Proc. Natl. Acad. Sci., USA, 81:5369-5373.
Morrison et al. (1984), Proc. Natl. Acad. Sci., USA, 81:6851-6855.
Nueberger et al. (1984), Nature, 312:604-608.
Potter et al. (1984), Proc. Natl. Acad. Sci., USA, 81:7161-7165.
Nueberger et al. (1984), Nature, 314:268-270.
Jones et al. (1986), Nature, 321:522-525.
Sahagan et al. (1986), The Journal of Immunology, 137(3):1066-1074.
Sun et al. (1986), Hybridoma, 5(Suppl. 1):S17-S20.
Sun et al. (1987), Proc. Natl. Acad. Sci., USA, 84:214-218.
Liu et al. (1987), The Journal of Immunology, 139(10):3521-3526.
Lui et al. (1987), Proc. Natl. Acad. Sci., USA, 84:3439-3443.
Shaw et al. (1987), The Journal of Immunology, 138(12):4534.
Brown et al. (1987), Cancer Research, 47:3577-3583.
Manser et al. (1984), Proc. Natl. Acad. Sci., USA, 81:2470-2474.
Short et al. (1988), Nucleic Acids Research, 16:7583-7600.
Queen et al., PNAS, 86:10029, 1989.
Riechmann et al. Nature 332:323-327 (1988).
Muraro et al. Cancer REsearch 48:4588-4596 (1988).
Anderson W. H. Kerr
Gourlie Brian B.
Kaplan Donald A.
Mezes Peter S.
Rixon Mark W.
Cunningham Thomas M.
Kimble Karen L.
Scott Mark S.
The Dow Chemical Company
LandOfFree
Family of high affinity, modified antibodies for cancer treatmen does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Family of high affinity, modified antibodies for cancer treatmen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Family of high affinity, modified antibodies for cancer treatmen will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2334401